On October 12, 2021 CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, reported that acceptance of an oral presentation and a poster presentation at The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, held virtually and in-person in Washington, DC, November 10-14, 2021 (Press release, CG Oncology, OCT 12, 2021, View Source [SID1234591115]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CG Oncology will present preliminary safety and efficacy data from CORE1, an ongoing Phase 2 clinical trial of CG0070 in combination with KEYTRUDA (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

Under a previously announced clinical collaboration with Merck relating to the investigation of CG0070 used in combination with pembrolizumab, the goal of CORE1, which will enroll up to 35 patients, is to evaluate the safety and efficacy of CG0070 plus KEYTRUDA for the treatment of NMIBC unresponsive to BCG.

More information about the study can be found at www.clinicaltrials.gov (NCT04387461).

Details of the oral presentation are as follows:

CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Abstract Number: 955
Presenter: Roger Li, M.D., Moffitt Cancer Center
Session Date & Time: Saturday, November 13, 2021 from 12:15-12:30pm EST
Category: Late-Breaking Oral Abstract Session

In addition, CG Oncology will present an overview of trial design and methodology of BOND3, an ongoing global Phase 3 trial with CG0070 as a monotherapy for the treatment of patients with NMIBC unresponsive to BCG. The goal of BOND3, which will enroll 110 patients, is to evaluate the safety and efficacy of CG0070 as a monotherapy for the treatment of NMIBC unresponsive to BCG.

More information about the study can be found at www.clinicaltrials.gov (NCT04452591).

Details of the poster presentation are as follows:

A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
Abstract Number: 426
Presenter: Edward Uchio, M.D., UC Irvine Health, Department of Urology
Session Date & Time: Friday, November 12, 2021 and Saturday, November 13, 2021 from 7:00am-8:30pm EST
Category: Poster Abstract Session

Full abstracts of both presentations will be available on the SITC (Free SITC Whitepaper) website on November 10, 2021.